Clara Correa-Paz, María Pérez-Mato, Mathys Bellemain-Sagnard, Marco González-Domínguez, Pauline Marie, Lara Pérez-Gayol, Esteban López-Arias, Lucia Del Pozo-Filíu, Sonia López-Amoedo, Ana Bugallo-Casal, María Luz Alonso-Alonso, María Candamo-Lourido, María Santamaría-Cadavid, Susana Arias-Rivas, Manuel Rodríguez-Yañez, Ramón Iglesias-Rey, José Castillo, Denis Vivien, Marina Rubio, Francisco Campos
Alteplase (rtPA) remains the standard thrombolytic drug for acute ischemic stroke. However, new rtPA-derived molecules, such as tenecteplase (TNK), with prolonged half-lives following a single bolus administration, have been developed. Although TNK is currently under clinical evaluation, the limited preclinical data highlight the need for additional studies to elucidate its benefits. The toxicities of rtPA and TNK were evaluated in endothelial cells, astrocytes, and neuronal cells. In addition, their in vivo efficacy was independently assessed at two research centers using an ischemic thromboembolic mouse model...
March 4, 2024: Journal of Cerebral Blood Flow and Metabolism